Cost-utility analysis of using paliperidone palmitate in schizophrenia in China

Frontiers in Pharmacology

Pharmacology

Rui Luo¹  He Lu²  Hengfen Li³ 

[1] Department of Psychiatry, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China;Department of Radiology, The People’s Hospital of Jiawang District of Xuzhou, Xuzhou, Jiangsu, China;null;

关键词: paliperidone palmitate;    schizophrenia;    cost-utility analysis;    China;    Markov;   

DOI  :  10.3389/fphar.2023.1238028

 received in 2023-06-12, accepted in 2023-07-24,  发布年份 2023

来源: Frontiers

【 摘 要 】

Objective: Long-acting injections (LAIs) of paliperidone palmitate have been shown to improve medication adherence and relieve psychotic symptoms. However, the specific cost-utility analysis of these LAIs in schizophrenia in China remains unclear.Methods: A multi-state Markov model was constructed to simulate the economic outcomes of patients with schizophrenia in China who received paliperidone palmitate 1-month formulation (PP1M), paliperidone palmitate 3-month formulation (PP3M), and paliperidone extended-release (ER). A cost-utility analysis was conducted, mostly derived from published literature and clinical databases. All costs and utilities were discounted at a rate of 5% per annum. The primary outcome measure was the incremental cost-effectiveness ratios (ICERs). A series of sensitivity analyses were also applied.Results: After 20 years, compared to ER, using PP1M resulted in an increased discounted cost from $36,252.59 to $43,207.28. This increased cost was associated with a gain in quality-adjusted life years (QALYs) from 8.60 to 9.45. As a result, the ICER for PP1M was estimated to be $8,247.46/QALY, which was lower than the willingness-to-pay (WTP) threshold of $12,756.55/QALY. When using PP3M instead of ER, the incremental cost was $768.81 and the incremental utility was 0.88 QALYs, projecting an ICER of $873.13/QALY, which was also lower than the WTP threshold of $12,756.55/QALY. The univariate sensitivity analysis showed that the costs of PP1M, PP3M, and ER had the greatest impact on ICERs. The probability sensitivity analysis (PSA) revealed that when the WTP thresholds were $12,756.55/QALY, the probability of PP1M and PP3M being cost-effective was 59.2% and 66.0%, respectively.Conclusion: From the Chinese healthcare system perspective, PP3M and PP1M are both more cost-effective compared to ER, and PP3M has notable cost-utility advantages over PP1M.

【 授权许可】

Unknown   
Copyright © 2023 Luo, Lu and Li.